Angiotensin-converting enzymeI inhibitors: Are there significant clinical differences?  by Jessup, Mariell
1248 
Editorial Comment 
JACC Vol. 13, No. 6 
May 1989: 1248-50 
Angiotensin-Converting Enzyme 
Inhibitors: Are There Significant 
Clinical Differences?* 
MARIELL JESSUP, MD, FACC 
Philadelphia, Pennsylvania 
The comparison of lisinopril with captopril in the treatment 
of heart failure by Giles and coworkers (l), published in this 
issue of the Journal, is a welcome first step toward the 
rational selection of an angiotensin-converting enzyme 
(ACE) inhibitor. In this study, lisinopril improved left ven- 
tricular ejection fraction and exercise capacity in subsets of 
patients in which captopril had no effect, and this is the first 
such comparison to show that clinical benefits occur more 
often with a specific ACE inhibitor. But, at our present level 
of understanding, we are ill prepared to comment on the 
mechanisms by which lisinopril effected these salutary re- 
sults. The study underscores how little we know about the 
entire class of ACE inhibitors. 
Mechanisms of beneficial effects of ACE inhibitors in heart 
failure. With the advent of these drugs for use in congestive 
heart failure came a rationale that initially appeared sound. 
The role of the renin-angiotensin system in the pathogenesis 
of heart failure had been well described (2,3). The acute 
hemodynamic response to oral ACE inhibitors, i.e., a reduc- 
tion in right and left ventricular filling pressures and systemic 
vascular resistance with a concomitant increase in cardiac 
index, was shown to be directly related to plasma renin 
activity and attendant with reductions in plasma angiotensin 
II, aldosterone and plasma ACE activity (4-7). Most impor- 
tant, the clinical benefits of ACE inhibitors in the manage- 
ment of patients with heart failure have been unequivocally 
demonstrated in numerous controlled trials (6,8-10). The 
hypothesis that inhibition of circulating ACE activity in 
heart failure would diminish the deleterious effects of plasma 
angiotensin II and thereby provide symptomatic relief to 
patients had been proved. But this theory does little to 
explain why lisinopril may be more efficacious than capto- 
pril. 
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Other observations are also inconsistent with this simple 
hypothesis. There is little or no correlation between values 
for systemic vascular resistance in heart failure and plasma 
renin or norepinephrine (11). Neither the acute hemody- 
namic response nor the pretreatment plasma renin activity 
predicts the long-term clinical response to ACE inhibitors in 
patients with hypertension or heart failure (12-14). In animal 
vascular preparations, both captopril and enalaprilat can be 
shown to reduce mean arterial pressures for ~24 h whereas 
ACE activity is inhibited for only approximately 6 h (15). 
Intracoronary infusion of enalaprilat produces both a selec- 
tive vasodilation of the coronary arteries and a negative 
inotropic effect on left ventricular contractility in patients 
with dilated cardiomyopathy (16), in contrast to the effects 
seen with systemic administration of the ACE inhibitors 
(17). Finally, long-term consequences of ACE inhibition on 
exercise capacity and renal function in heart failure appear 
to be more dependent on complex alterations in regional 
vascular tone than on hemodynamic manipulations. Mancini 
et al. (18) showed that improvement in maximal oxygen 
uptake after 8 weeks of captopril therapy occurred only in 
those patients whose peak skeletal muscle blood flow also 
increased. 
Several investigators have described the various effects 
of ACE inhibition on renal funciton (6,19,20). Over the short 
term, ACE inhibition leads to a pronounced decrease in 
renal plasma flow and glomerular filtration rate concomitant 
with a decrease in mean arterial pressure; the magnitude of 
the decrease correlates with baseline plasma renin and is 
paralleled by a reduction in sodium and water excretion. 
With long-term treatment, despite a similar decrease in mean 
arterial pressure, there is an increase in renal plasma flow, 
and baseline glomerular filtration rate, water and sodium 
excretion are maintained. Moreover, even those patients 
who develop elevations of serum urea and creatinine con- 
centrations during therapy manifest meaningful clinical less- 
ening of their symptoms of heart failure, discordant with 
their deteriorating renal profile. The underlying theme com- 
mon to these observations is that ACE inhibitors seem to 
effect organ-specific physiologic adaptations in vascular tone 
or organ function that require time (or duration of long-term 
therapy) to be clinically apparent. 
The renin-angiotensin system in various organs and tissues. 
Further investigations into the mechanisms of ACE inhibi- 
tion in hypertension have atforded us some insight into the 
role of the renin-angiotensin system in various tissues (Table 
1). Researchers have identified components of the renin- 
angiotensin cascade in blood vessel walls, kidney, heart, 
adrenal gland and brain. Angiotensin II, whether systemi- 
cally derived or tissue specific, has been shown to have 
locally mediated functions. This growing list includes en- 
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Renal blood Row, glomerular filtration rate and 
hemodynamics. sodium reabsorption 
and prostaglandin and antagonism of the diverse angiotensin 
effects at that site. For instance, differences among the ACE 
inhibitors on brain ACE activity will be partly dependent on 
the lipid solubility of a given metabolite and the ability of a 
drug to cross the blood-brain barrier (25). 
Blood vessel 
Heart 
Vascular tone. vascular hypertrophy 




Aldosterone secretion, catecholamine release 
Thirst. behavior, blood pressure, vasopressin 
and catecholamine release 
Pituitary ACTH. gonadotropin hormone. prolactin 
release 
ACTH = adrenocorticotropin. Adapted from Dzau (21). with permisston. 
The tantalizing evidence provided by Giles et al. (1) and 
other investigators (26) suggests that there are real differ- 
ences between ACE inhibitors. However, the conceptual 
framework for understanding the mechanisms responsible 
for these differences is fragile at best. Unfortunately, until 
more research is accomplished, the choice of an ACE 
inhibitor for the patient with heart failure rests more on 
whimsy than on wisdom. 
hancement of norepinephrine release from noradrenergic 
nerve endings, stimulation of vasopressin, development of 
vascular or myocardial hypertrophy, influence on myocar- 
dial metabolism during ischemia and, in the brain, stimula- 
tion of water drinking behavior. Likewise, ACE inhibition of 
tissue angiotensin will result in local alterations of each 
organ. For example, in spontaneously hypertensive rats, 
inhibition of ACE activity in the aorta was better correlated 
with the magnitude and duration of the hypotensive action of 
several ACE inhibitors than with serum enzyme activity 
(22). In the same animal model, infusion of captopril into the 
cerebral ventricle for several weeks led to a marked attenu- 
ation of the development of hypertension in contrast to the 
negligible effect of long-term systemic therapy (23). Finally, 
inhibition of the angiotensin-converting enzyme is responsi- 
ble for the stimulation of bradykinin and the formation of 
prostaglandin, with their own attendant local or systemic 
effects. 
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